Mark Shaefer, PharmD, FCCP
​Clinical Science Head- Anti-Viral

Mark has over twenty-five years of HIV and antiviral pharmaceutical experience. His intensive pharmaceutical experience is complemented by expertise in clinical pharmacy, academic teaching, and research.

Education: After completing an undergraduate degree in Biology from the University of California at San Diego, Mark earned his PharmD in 1985 from University of California at San Francisco followed by a Clinical Pharmacy Residency at the University of Nebraska Medical Center. Mark has held academic appointments as Assistant and Associate Professor at the University of Nebraska, is widely published with more than 75 peer-reviewed publications and is a reviewer for multiple journals.
​
Experience: Mark’s pharmaceutical career in HIV and anti-viral research follows a path of progressive responsibilities from Burroughs Wellcome where he worked on acyclovir and valaciclovir to Glaxo Wellcome, where he oversaw HIV clinical trials, and to GSK, where his expertise over the next nine years led him to more senior roles including Group Director and Acting Vice President.  Mark left GSK to join ViiV Healthcare during its founding in 2009. He was initially the Head of North American Medical Affairs and then progressed to a position as Global Medical Lead for Cabotegravir, a long-acting injectable drug for treatment and prevention of HIV.  He joined Hengrui USA in early 2021 in his current role as Executive Director and Clinical Head for Antivirals.